

WEEKLY MARKET OUTLOOK

6 - 12 March 2017

WEEKLY MARKET OUTLOOK - An Overview

| | | |
|----|------------------------|--|
| p3 | Economics | Fed Takes Back Center Stage - Peter Rosenstreich |
| p4 | Economics | No Wage Growth Environment - Yann Quelenn |
| p5 | Economics | AUD Set To Decline Further - Arnaud Masset |
| p6 | Themes Trading | BioTech Revolution |
| p7 | Themes Trading | Swiss Smart Beta |
| p8 | Risk Disclosure | |


Economics

Fed Takes Back Center Stage

In our view the last straw fell this week as FOMC committee member Brainard seemingly reversed her long standing skepticism of a near term rate hike. We now expect the US policy path to include a hike in March and September. Brainard pointed to lowered concern over the growth outlook in Europe and China. Given Brainard's long-standing dovish bias support of tightening should be viewed as an important step. Markets have rapidly pulled forward the Fed next rate hike from 20% probability of a 25bp hike just two weeks against over 90% today. US front end yields reinforced expectations and have supported the USD rally.

If we are correct, a majority of USD buying has already been priced in (judging from vol) but USD remains underpriced for additional tightening to continue through 2017. In the mid-term, given the mounting political risk in Europe we continued to see EURUSD grinding lower.

First, US economic data has improved along the line with momentum in global growth. China factory activity expanded faster than expected at manufacturing PMI rose to 51.6. While South Korea exports grew at the fastest pace in five years with shipments to China increasing 28.7% y/y. Domestically, the US manufacturing sector grew for a sixth consecutive month as Purchasing manager index surged to 57.7 and factory orders climbed 1.3%. Second, inflation including core pace has quickened more than expected. Annual core PCE, the Fed favorite measure of price pressures, remains elevated at 1.7% while core CPI has climbed to 2.3%. Third, the rhetoric from Fed members including history dovish members increasingly sounds hawkish, suggesting a bit of urgency in policy setting. Finally, President Trump's conciliatory address to congress has lowered the potential political risk that was obscuring Fed's policy pricing. With the markets principally focused on economic fundamental and monetary policy, and not political noise, the reality of data indicted Fed need to act. Our expectation of only two hikes in 2017 is based on the fact that real wage growth remains subdued.



Economics

No Wage Growth Environment

Since reaching its lowest level in a year against the dollar in December, the yen continues to strengthen. However, the BoJ still appears to be unable to stimulate the economy and fundamental data are somewhat lukewarm. Industrial production came in earlier last week at -0.8% m/m for January after financial markets were expecting a positive read. Retail data are also concerning, household spending is on its way down, 1.2% in January. Ironically, upside pressures on the yen continues despite its economy being out of control. Japan's economy is clearly a market risk indicator.

For the first time since 2015, Japanese inflation has become positive. This may be seen as positive for Shinzo Abe and the Bank of Japan but the print is only of 0.1% y/y. The inflation target of 2% still seems far off. Of course, the most likely cause are petrol prices which have jumped since last year.


Indeed, since Trump's election last November there were hopes that Japan's inflation will eventually start picking up. The yen has weakened in the last few months. We recall that Japan has battled with inflation for the past two decades and the ultra-loose monetary policy has not worked yet. The BoJ's strategy to control Japan's yield curve may be a more sustainable strategy in the medium-term.

Japanese policymakers are still expecting the Fed to raise rates in order to hold off some pressures from the economy. However, there are still important uncertainties on the Fed rate path tightening. This is why we remain cautious as there are definitely room for further disappointment. Uncertainties over Trump's economic policies loom large.

It is also worth noting that retail sales have increased for the third consecutive month with a 0.5% m/m for January (1% increase annualized). Furthermore, wage growth slowed in December, which should reflect at some point in the retail sales. The truth is that wages are not at a sufficient level to support the economic recovery especially knowing that, once inflation is stripped away, wage growth for 2016 will in fact be negative.

Other fundamental data is positive, unemployment is very low, 3% and the number of jobs per applicant is lying at an amazing 26-year high. Yet, companies are still reluctant to increase wages, which would support the economic recovery

Japan: Inflation positive for the first time since 2015



Economics


AUD Set To Decline Further

The Australian dollar has been the best performing currency among the G10 complex during the two first months of the year. The Aussie rose more 6% against the greenback and recovered from around \$0.72 to around \$0.77. This sustainable appreciation of the Aussie is mostly the results of two factors: Firstly, the broad dollar depreciation was especially marked against high-yielding currencies such as the Aussie and the Kiwi but also against safe haven currencies such as the Japanese yen and the Swiss franc. This move was due in large part to growing impatience of investors about the lack of details regarding Trump's stimulus plan. Secondly, the sharp increase in iron prices - together with the broad-based recovery in commodity prices - has helped boost expectations for the country's growth outlook. Indeed, the Aussie economy is highly dependent on exports (around 20% of GDP) and its dependence on China's health is also very high as roughly 34% (12-month average) of its exports go to the "Middle Kingdom".

We do not exclude the RBA to cut rates next Tuesday but in our opinion it appears very unlikely as the AU-US yield spread continues narrow. We anticipate AUD/USD to return quickly toward \$0.75 and do not rule out further weakness for the pair should the dollar rally continue with \$0.74 as the next target.

Despite this encouraging note, dark clouds are gathering on the horizon as the two factors mentioned above are losing momentum. Indeed, China's iron ore port inventory rose dramatically this year and reached almost 130 million tons as of February 24th. On the other hand, over the same period, steel production continued to inch lower, suggesting that there is a strong imbalance between demand and supply. Finally, on a trade-weighted basis the Aussie is back to levels last seen in summer 2015, which makes the RBA very unhappy with the situation. Indeed, the central bank has reiterated many times that the Aussie is overvalued and may be ready to take some action to adjust this situation. Taking into account the two factors exposed above, we believe that the Aussie rally is definitely over and that the ongoing correction has some legs. We do not

2-year yield spread slid to 0.50%



Themes Trading

BioTech Revolution

Trump negative comments over the pharma industry has now died down allowing Biotech stocks to recover. The pharmaceutical industry is going through a minor revolution. Biotechnology has a broad mandate, covering a wide range of processes for transforming living organisms for human purposes. However, this theme focuses on a new breed of companies that have joined the race to use modern technology to create healthcare products. These companies harness cellular and bio-molecular processes to develop technologies and products to fight disease. Exploding R&D costs have forced traditional pharma companies to look to smaller, more agile, technology-driven firms as the primary pipeline for innovation. With public and private investors and big pharma all expecting the next big breakthrough to come from this dynamic sector, valuations are on the rise.

We built this theme by filtering on firms with a market capitalization of over \$1 billion and positive sales growth over the past two years, ensuring that they have sufficient cash flow to fund the next blockbuster.

<https://www.swissquote.ch/url/investment-ideas/themes-trading>



Buy structured product

BioTech Revolution

Science • Biology • Health

LONG TERM HIGH RISK

▲ 7.35% 1-month return

| | |
|---------------------|----------|
| Since inception | ▲ 9.25% |
| 1-month return | 7.35% |
| Return day | 0.65% |
| Est. dividend yield | 0.00% |
| Inception date | 01/02/16 |

[See portfolio details](#)

[Buy structured product](#)




Themes Trading

Swiss Smart Beta

Swiss stocks have a reputation of being high quality and tend to provide stable returns during times of geopolitical uncertainty. With President Trump, Brexit, European elections and global protectionism, the world has become significantly more unpredictable. This portfolio sources high-dividend Swiss stocks and provides an active quantitative overlay to optimize risk/reward potential.

The Swiss Smart Beta theme consists exclusively of stocks from the Swiss Performance Index (SPI). The selection process identifies stocks with a high dividend yield and a market capitalization in excess of CHF 100 million. Illiquid stocks are screened for constant bid-ask spread and daily average dollar volume traded. To enhance risk diversification, the portfolio is weighted using an equally-weighted risk contribution approach. In summary, this means the allocation is calculated in such a way that each stock contributes on an equal basis to the total risk of the portfolio. This approach allows for low volatility and, in so doing, increases the risk/reward ratio.

<https://www.swissquote.ch/url/investment-ideas/themes-trading>



Buy structured product

Swiss Smart Beta

Culture • Economy • Industry

LONG TERM | LOW RISK

▲ 3.29% 1-month return

| | |
|---------------------|----------|
| Since inception | ▲ 12.56% |
| 1-month return | 3.29% |
| Return day | -0.20% |
| Est. dividend yield | 0.00% |
| Inception date | 01/09/16 |

[See portfolio details](#)

[Buy structured product](#)



DISCLAIMER

While every effort has been made to ensure that the data quoted and used for the research behind this document is reliable, there is no guarantee that it is correct, and Swissquote Bank and its subsidiaries can accept no liability whatsoever in respect of any errors or omissions, or regarding the accuracy, completeness or reliability of the information contained herein. This document does not constitute a recommendation to sell and/or buy any financial products and is not to be considered as a solicitation and/or an offer to enter into any transaction. This document is a piece of economic research and is not intended to constitute investment advice, nor to solicit dealing in securities or in any other kind of investments.

Although every investment involves some degree of risk, the risk of loss trading off-exchange forex contracts can be substantial. Therefore if you are considering trading in this market, you should be aware of the risks associated with this product so you can make an informed decision prior to investing. The material presented here is not to be construed as trading advice or strategy. Swissquote Bank makes a strong effort to use reliable, expansive information, but we make no representation that it is accurate or complete. In addition, we have no obligation to notify you when opinions or data in this material change. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments.

This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning Swissquote Bank, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. Swissquote Bank does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investment losses. Investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are for information purpose only and are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of Swissquote Bank as a result of using different assumptions and criteria. Swissquote Bank shall not be bound or liable for any transaction, result, gain or loss, based on this report, in whole or in part.

Research will initiate, update and cease coverage solely at the discretion of Swissquote Bank Strategy Desk. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. Swissquote Bank is under no obligation to update or keep current the information contained herein and not liable for any result, gain or loss, based on this information, in whole or in part.

Swissquote Bank specifically prohibits the redistribution of this material in whole or in part without the written permission of Swissquote Bank and Swissquote Bank accepts no liability whatsoever for the actions of third parties in this respect. © Swissquote Bank 2014. All rights reserved.